egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none ALISO VIEJO, Calif., Oct. 21, 2026 /PRNewswire/ -- egnite, Inc., a technology company advancing...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.